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Abstract
The responseof radiation-induced fibrosarcoma1 (RIF-1)
tumors treated with the vascular-disrupting agent
(VDA) ZD6126 was assessed by in vivo and ex vivo 1H
magnetic resonance spectroscopy (MRS) methods.
Tumors treated with 200 mg/kg ZD6126 showed a sig-
nificant reduction in total choline (tCho) in vivo 24 hours
after treatment, whereas control tumors showed a sig-
nificant increase in tCho. This response was investi-
gated further within both ex vivo unprocessed tumor
tissues and tumor tissue metabolite extracts. Ex vivo
high-resolution magic angle spinning (HRMAS) and 1H
MRS of metabolite extracts revealed a significant re-
duction in phosphocholine and glycerophosphocholine
in biopsies of ZD6126-treated tumors, confirming in vivo
tCho response. ZD6126-induced reduction in choline
compounds is consistent with a reduction in cell mem-
brane turnover associated with necrosis and cell death
following disruption of the tumor vasculature. In vivo
tumor tissue water diffusion and lactate measurements
showed no significant changes in response to ZD6126.
Spin–spin relaxation times (T2) of water and metabolites
also remained unchanged. Noninvasive 1H MRS mea-
surement of tCho in vivo provides a potential biomarker
of tumor response to VDAs in RIF-1 tumors.
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Introduction
A functional vascular network is essential for the survival
and growth of solid tumors [1,2]. The dependence of tumor
cells on a nutritive blood supply has resulted in the tumor
vasculature becoming an attractive therapeutic target.
Vascular-disrupting agents (VDAs) have been developed
to exploit differences between normal and tumor vascular
endothelium, with the aim of selectively destroying tumor
blood vessels while leaving normal vessels unaffected [3,4].
N-acetylcolchinol-O-phosphate (ZD6126) is a small-molecule
VDA that is shown to have significant antitumor activity against
rodent and human tumor model systems [5–9] and against
human tumor vasculature [10]. It is a water-soluble phosphate
prodrug of the tubulin-binding agent N-acetylcolchinol that
inhibits tubulin polymerization, disrupting the microtubule cyto-
skeleton [11]. Following ZD6126 treatment, disruption of the
tubulin cytoskeleton in proliferating endothelial cells leads to
endothelial cell detachment, tumor vascular shutdown, and,
ultimately,massive central hemorrhagic necrosis [5,6]. A surviv-
ing rim of tumor cells is characteristically seen histologically
following treatment. As a consequence, VDAs characteristically
induce tumor growth delay but not tumor regression, as the
tumor regrows from this viable rim. Thus, the clinical develop-
ment of VDAs will be greatly assisted by the use of biomarkers
that are sensitive to disrupted tumor perfusion. To this end,
noninvasive imaging methods, such as magnetic resonance
imaging (MRI) [9,10] and positron emission tomography [12],
are being exploited.
Magnetic resonance spectroscopy (MRS) methods provide
noninvasive measurements of tumor biochemistry. Localized
in vivo 1H MRS techniques have been developed to quantify
the concentration (in mM) of tumor total choline (tCho; an im-
portant metabolic marker that is associated with membrane
turnover, malignancy, and tumor grade) [13–15] and lactate
(another significant tumor metabolite that is associated with
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glycolysis, acidosis, and hypoxia) [13–17]. Choline, phos-
phocholine (PC), and glycerophosphocholine (GPC) all con-
tribute to the tCho trimethylamino resonance detected at
3.23 ppm, but they cannot be individually resolved in vivo
due to the typically low magnetic field homogeneity achiev-
able in vivo. To understand the individual contributions of
choline compounds to in vivo tCho resonance, both high-
resolution magic angle spinning (HRMAS) 1H MRS, from
which well-resolved spectra can be obtained from a few
milligrams of unprocessed solid tumor samples [18–20],
and 1H MRS of sequential tumor metabolite extractions have
been used [21].
Water diffusion within tumors is another property of tumors
that is currently being intensively investigated. Apparent
water diffusion coefficient (ADC), measured in vivo by 1H
MRS, is sensitive to the biophysical characteristics of tis-
sues, including the fraction of extracellular space. Several
studies have shown the potential of ADC as a biomarker of
therapeutic response in tumors [22–25].
We have previously shown that 200 mg/kg ZD6126 in-
duces massive hemorrhagic necrosis in RIF-1 tumors
24 hours after treatment [9]. The aims of this study were to
investigate the utility of in vivo 1H MRS to provide biomarkers
of response to ZD6126 in RIF-1 tumors, and to provide any
validation of these biomarkers with ex vivo HRMAS and 1H
MRS of tumor extracts following treatment.
Methods
Animals and Tumors
All experiments were performed in accordance with the
local ethical review panel, the UK Animals (Scientific Proce-
dures) Act 1986, and the United Kingdom Coordinating
Committee on Cancer Research guidelines [26]. Murine
radiation-induced fibrosarcoma 1 (RIF-1) was grown subcu-
taneously in the flanks of C3H female mice (n = 12) [27].
Tumor volume was calculated by measuring length (l ), width
(w), and depth (d ) using calipers and the formula: lwd(k / 6).
Administration of Anesthesia and Dosage of ZD6126
The mice were anesthetized with a 10-ml/kg intraperito-
neal (i.p.) injection of fentanyl citrate (0.315 mg/ml) plus
fluanisone (10 mg/ml) (Hypnorm; Janssen Pharmaceutical
Ltd., Oxford, UK), midazolam (5 mg/ml) (Hypnovel; Roche,
Welwyn Garden City, Herts, UK), and water (1:1:2). ZD6126
was obtained from AstraZeneca (Cheshire, UK) and formu-
lated in 20% of 5% sodium carbonate and 80% phosphate-
buffered saline, yielding a clear solution at ca. pH 7.
In Vivo 1H MRS
Anesthetized mice were placed in the bore of a 4.7-T
horizontal magnet fitted with a 10-G/cm 12-cm-bore high-
performance auxiliary gradient insert interfaced to a Varian
Unity Inova spectrometer (Varian Instruments, Palo Alto,
CA), so that the tumors hung on a two-turn 1H radiofrequency
coil of 15 mm diameter. Body temperature was maintained
with a water-heated pad placed over the mouse. Voxels were
selected from scout gradient echo images, and localized
shimming yielded linewidths on the order of 20 to 30 Hz.
PRESS localization with water suppression was used to
detect choline, with a repetition time of 2 seconds, 64 tran-
sients, and echo times of 20, 68, 136, 272, and 408 milli-
seconds. Water suppression included selective excitation of
water signal by 14-millisecond Gaussian pulse followed by
dephasing gradients in three orthogonal directions in repeti-
tion time delay. For unsuppressed water, 16 transients were
acquired with the same acquisition parameters as above,
except with a lower receiver gain. A multiple quantum coher-
ence (MQC) editing sequence with a single-shot outer
volume–saturated localization [28] and a repetition time of
3 seconds was used to detect lactate signal. A localized
STEAM sequence with diffusion-sensitizing gradients in
echo-time periods was used to separately obtain diffusion-
weighted (DW) 1H MRS data for each orthogonal (x, y, z)
direction. The acquisition parameters for DW-MRSwere TE =
24milliseconds, TM = 100milliseconds, TR = 3 seconds, d = 6
milliseconds, and D = 112 milliseconds, with diffusion gra-
dients increasing from 0 to 13 G/cm with a 1-G/cm interval.
Corresponding b values were 0, 2731, 10,924, 24,579,
43,696, 68,276, 98,317, 133,820, 174,786, 221,214,
273,104, 330,455, 393,269, and 461,545 sec/cm2.
After pretreatment 1H MRS measurements, saline or
200 mg/kg ZD6126 was administered intraperitoneally, and
1H MRS was repeated 24 hours later. Immediately after
posttreatment in vivo MRS measurements, anesthetized
mice were sacrificed by cervical dislocation and the tumors
were rapidly excised and either frozen intact for HRMAS
MRS or freeze-clamped in liquid nitrogen for high-resolution
1H MRS of tissue extracts.
In Vivo 1H MRS Data Analysis
MRUI software [29], using the AMARES [30] algorithm in
the time domain, was used for data processing and reso-
nance fitting. The method included metabolite lineshape
correction and zero-order phasing using a water reference
signal [31], removal of residual water signal in the range of
4.5 to 5.0 ppm using Hankel Lanczos Singular Value De-
composition, and direct current offset calculated from the
last 100 data points. The first data point in free induction
decay was excluded to minimize the contribution from broad
signals underlying the whole spectrum, which, when present,
can result in an overestimation of metabolite signals. Gauss-
ian lineshapes were assumed for the estimation of metab-
olite peak areas. Prior knowledge used to constrain fitting
parameters included the application of equal linewidths of
tCho and total creatine (tCr; creatine plus phosphocreatine)
resonances (with the assumption that shimming dominates
linewidth) [17], and also that the chemical shifts of metabo-
lite resonances were limited to 0.05 ppm about their ex-
pected values of 3.22 and 3.03. The tCho, tCr, and water
peak areas were plotted as a function of echo time, and the
intercept (M0) and metabolite T2 values were determined
by assuming a monoexponential decay function using the
Levenberg-Marquardt algorithm.
Response of RIF-1 Fibrosarcomas to ZD6126 Madhu et al. 561
Neoplasia . Vol. 8, No. 7, 2006
Metabolite concentrations were calculated using tumor
water as a reference, assuming tissue water was 80% (88 M
protons), according to the equation [13,14]:
½metabolite ¼ ðmetabolite=waterÞTE¼ 0WcðNw=NmÞðAVnRGcÞ
where [metabolite] = metabolite concentration; (metabolite/
water)TE=0 = ratio of metabolite and water intercepts at TE = 0,
as determined from individual T2 fits; Wc = water concentra-
tion (44 M);Nw = number of protons in water (2);Nm= number
of protons contributing to metabolite resonance (for tCho,
Nm= 9; for tCr, Nm = 3); AVn = normalization factor for the
number of averages; and RGc = receiver gain correction
factor. The corrections for the number of averages and
receiver gains were needed because they were different for
the acquisition of water and metabolite spectra. Quantitation
of lactate was not possible because the signal observed with
theMQC editing sequence was acquired at a fixed echo time;
thus, an uncorrected lactate/water signal ratio was deter-
mined using water intercept values calculated from T2 curves
at TE = 0.
For analysis of diffusion-weighted data, the plots of nor-
malized water signal (M /M0) against b values were fitted with
a stretched exponential model [M / M0 = exp{  (bDDC)a}],
resulting in the estimation of a heterogeneity index (a) and
distributed diffusion coefficient (DDC) [32]. The Levenberg-
Marquardt algorithm was used for optimization. The average
values of DDC and a were estimated by DDC = (DDCxx +
DDCyy + DDCzz) / 3 and a= (axx + ayy + azz) / 3.
HRMAS 1H MRS
Frozen tumor tissue (12 ± 3 mg) was transferred to a
4-mm zirconium oxide HRMAS rotor. Deuterium oxide (10 ml)
was added for field frequency locking. All HRMAS experi-
ments were performed on a 600-MHz (14.1-T) Bruker
AVANCE spectrometer (Bruker Biospin, Coventry, UK) with
a spin rate of 4000 ± 2 Hz at 277 K. Spectra were acquired
with a CPMG pulse sequence [90  (s  180)n  s  acq] as
a T2 filter to remove broad resonances arising from slowly
tumbling macromolecules and lipids. The interpulse delay
s was 250 microseconds, and spectra were obtained with
128 transients, 32,000 data points, and 8 kHz spectral width.
The 90j pulse was adjusted for individual samples and
varied from 13.5 to 14.5 microseconds. T2 measurements
were performed by varying the effective T2 filter time from
100 to 1000 milliseconds in six increments. Spectral pro-
cessing included 0.5-Hz apodization, Fourier transformation,
and first-order phase correction. A monoexponential decay
of metabolite signal with echo time was assumed to estimate
equilibrium magnetization (M0) and T2 values of metabolites.
M0 was used for quantitation of metabolites. The creatine
peak at 3.03 ppm was used as a chemical shift reference
[20]. tCr content [tCr = creatine (Cr) + phosphocreatine
(PCr)], which was obtained from the total extracted by
perchloric acid (PCA), methanol, and chloroform extractions
(see later) for each tumor, was used as an internal standard
for the quantitation of metabolites by HRMAS [20].
High-Resolution 1H MRS of Tissue Extracts
Tissue metabolites from frozen tissue were extracted
using PCA and methanol/chloroform methods [21]. Frozen
tumor tissue was ground to a fine powder using mortar and
pestle. One part of tissue plus four parts of 6% PCA were
homogenized and centrifuged, and the resulting supernatant
was neutralized. After lyophilization, the sample was used
for high-resolution 1H MRS. Methanol and chloroform (2:1;
3 ml/g) were added to the residual pellet (after PCA extrac-
tion) and homogenized. The mixture was left on ice for
15 minutes, and then chloroform and distilled water (1:1;
1 ml/g) were added to form an emulsion. Centrifuging the
sample resulted in a clear separation of the upper (methanol
and water) phase from the lower organic (chloroform) phase,
with the pellet in the middle. Both phases were carefully
separated and dried at room temperature. All dried samples
were then reconstituted in 1 ml of deuterium oxide, except
for chloroform-extracted metabolites that were taken up in
1ml of CDCl3, and 0.5ml of this sample was placed in a 5-mm
standard nuclear magnetic resonance tube. Sodium 3-tri-
methylsilyl-2,2,3,3-tetradeuteropropionate (50 ml, 5 mM)
was added as an external standard for chemical shift cali-
bration and quantitation of metabolites. Immediately before
MRS analysis, the pH of the samples was readjusted to 7
with PCA or potassium hydroxide. All high-resolution 1HMRS
data were acquired at 600 MHz (14.1 T) using a Bruker
AVANCE spectrometer. 1H MRS acquisition included presa-
turation of water using gated irradiation centered on water
frequency, a repetition time of 5 seconds, and 128 averages.
Results
Irrespective of treatment, the tumor volume of all RIF-1
tumors significantly increased over the 24-hour period of
study (Table 1). Localized PRESS 1H MRS yielded a well-
resolved tCho resonance at 3.23 ppm and a tCr resonance
at 3.03 ppm in all RIF-1 tumors in vivo. Representative
spectra from one RIF-1 tumor before and after treatment
with 200 mg/kg ZD6126 are shown in Figure 1. Lactate
signals were also detected in both pretreatment and post-
treatment MQC 1H spectra.
Individual tCho concentrations for all RIF-1 tumors before
and 24 hours after treatment with either saline or 200 mg/kg
ZD6126 are shown in Figure 2. All saline-treated tumors
showed an increase in tCho, whereas tCho decreased in all
ZD6126-treated tumors. The individual tumor tCho con-
centrations before and after treatment with either saline or
ZD6126, plotted as a function of tumor volume, are shown in
Figure 3. The in vivo 1H MRS data obtained from RIF-1
tumors are summarized in Table 1. A significant (P = .009)
reduction in the tCho of RIF-1 tumors was determined
24 hours after treatment with ZD6126, whereas tCho signifi-
cantly increased over 24 hours in saline-treated control
tumors. There were no significant changes in water T2, tCho
T2, tCr T2, and lactate/water ratio in either control or treated
cohorts. In vivo water DDC and the heterogeneity index a
showed no change in either saline-treated or ZD6126-
treated cohorts.
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The metabolite concentrations determined from unpro-
cessed tumor tissue by HRMAS 1H MRS and from high-
resolution 1H MRS of tissue extracts are summarized in
Table 2. Both methods revealed a significant reduction in
PC and GPC, but no change in free choline concentrations,
in ZD6126-treated RIF-1 tumors. The sum of free choline,
PC, and GPC (the metabolites that contribute to tCho reso-
nance detected in vivo) was calculated for eachMRSmethod
for comparison of in vivo and ex vivo tCho data. A highly
significant reduction in tCho was found in ZD6126-treated
unprocessed tumor tissue by HRMAS, but not in tissue
extracts determined by high-resolution 1H MRS. Both ex vivo
MRS methods revealed a significant reduction in tCr and
taurine following treatment with ZD6126. Alanine was also
found to be significantly reduced, as determined by HRMAS
1H MRS only. There were no significant changes in the
concentration of lactate, glycine, or acetate.
Figure 1. In vivo PRESS-localized 1H MRS spectra (TE = 136 milliseconds)
acquired from one RIF-1 tumor (a) before and (b) 24 hours posttreatment
with 200 mg/kg ZD6126.
Figure 3. tCho concentration plotted as a function of tumor volume for each
individual RIF-1 tumor investigated by in vivo 1H MRS.
Table 1. Summary of In Vivo 1H MRS Data Obtained from RIF-1 Tumors
before and 24 Hours after Treatment with Either Saline (n = 6) or 200 mg/kg
ZD6126 (n = 6).
Variable Saline ZD6126
Pretreatment Posttreatment Pretreatment Posttreatment
Volume (mm3) 458 ± 65 589 ± 85* 518 ± 52 671 ± 57y
tCho (mM) 4.43 ± 0.20 5.09 ± 0.17* 5.73 ± 0.46 2.40 ± 0.51*
tCr (mM) 4.81 ± 0.38 5.14 ± 0.76 4.56 ± 0.73 3.14 ± 0.57
Water T2
(milliseconds)
53.3 ± 1 52.8 ± 2 51.4 ± 1 46.9 ± 4
tCho T2
(milliseconds)
190 ± 13 157 ± 17 162 ± 14 142 ± 12
tCr T2
(milliseconds)
142 ± 12 133 ± 16 138 ± 12 116 ± 13
Lactate/water
(103)
3.79 ± 0.80 3.08 ± 0.95 3.06 ± 0.82 1.54 ± 0.68
DDC (106
cm2/sec)
5.39 ± 0.45 5.17 ± 0.48 4.72 ± 0.28 5.63 ± 1.30
Heterogeneity
index (a)
0.77 ± 0.03 0.77 ± 0.01 0.75 ± 0.02 0.75 ± 0.02
Values are mean ± SEM.
*P < .02, Student’s paired t test between pretreatment and posttreatment
values.
yP < .05, Student’s paired t test between pretreatment and posttreatment
values.
Figure 2. Line series of tCho concentration (mM) determined by in vivo 1H
MRS for each RIF-1 tumor (a) before and 24 hours after saline, and (b) before
and 24 hours after 200 mg/kg ZD6126, i.p.
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A comparison of the tCho concentrations of RIF-1 tumors
determined 24 hours after saline or ZD6126 by in vivo 1H
MRS, HRMAS 1HMRS, and high-resolution 1HMRSof tissue
extracts is shown in Figure 4. The ex vivo data measured in
micromoles per gram per wet weight were converted to
millimolars by dividing by a factor of 0.80 (mM = mmol/g per
wet weight per 0.8) to allow for a comparison with the in vivo
1H MRS data measured in millimolars [18,33]. Both in vivo
and HRMAS 1H MRS, but not high-resolution 1H MRS of
tumor extracts, revealed a significant reduction in tCho
concentration in ZD6126-treated tumors. Figure 5 summa-
rizes the tCho/tCr ratios for saline-treated and ZD6126-
treated tumors, as determined by in vivo 1H MRS, HRMAS
1H MRS, and high-resolution 1H MRS of tissue extracts.
There was no significant difference in the tCho/tCr ratio
in response to ZD6126 measured by the three different 1H
MRS methods.
Discussion
The aim of this study was to investigate the use of in vivo 1H
MRS to assess the metabolic status of RIF-1 tumors before
and 24 hours after treatment with 200 mg/kg ZD6126, a dose
and timing regime previously shown to induce massive
hemorrhagic tumor necrosis in this murine model [9]. Valida-
tion of in vivo response was sought using HRMAS 1H MRS
and high-resolution 1H MRS of tissue extracts. In addition, the
biophysical properties of tumor water T2, diffusion, and their
response to ZD6126 were also investigated.
Metabolite Response to ZD6126
A common observation in MRS studies of cancer is ele-
vation in the concentration of choline metabolites, although
the precise reasons for this are still unclear [34]. It has been
traditionally attributed to an increased biosynthesis of
membranes by rapidly proliferating tumor cells [35], and the
significant increase in the tCho concentration of control RIF-1
tumors over 24 hours reported herein is consistent with this.
Recent evidence suggests that, in addition to biosynthetic
pathways, mitogen-induced and oncogene-induced activa-
tion of phosphatidylcholine and phosphatidylethanolamine
metabolism can increase the accumulation of choline metab-
olites in tumor cells [36]. Upregulation of choline kinase,
which catalyzes the phosphorylation of choline to yield PC,
may also contribute [37].
The significant decrease in tCho concentration of RIF-1
tumors in vivo 24 hours after treatment with ZD6126, which
was observed despite continued tumor growth (Figure 3), is
consistent with reduced cell membrane turnover associated
with necrosis following disruption of the tumor vasculature.
This in vivo response biomarker was further validated by a
significant ZD6126-induced decrease in both PC and GPC
(key metabolites associated with membrane biosynthesis
that contribute to tCho resonance detected in vivo), as mea-
sured by HRMAS 1H MRS and high-resolution 1H MRS of
tissue extracts. Quantitative 1H MRS revealed a similar re-
sponse pattern of HT29 tumors after treatment with the VDA
Figure 4. tCho concentrations (mM) determined by in vivo 1H MRS of
unprocessed tissues, by HRMAS 1H MRS of extracts, and by HR 1H MRS
of tissue extracts of RIF-1 tumors 24 hours after treatment with saline or
200 mg/kg ZD6126. tCho determined in vivo and by HRMAS was significantly
reduced (**P < .02).
Figure 5. tCho/tCr ratios of RIF-1 tumors determined by in vivo 1H MRS,
HRMAS 1H MRS, and high-resolution 1H MRS of tissue extracts 24 hours
after treatment with either saline or 200 mg/kg ZD6126.
Table 2. Tumor Metabolite Concentrations (mmol/kg) Determined by 1H
HRMAS of Unprocessed Tissues and by High-Resolution 1H MRS of Tissue
Extracts of RIF-1 Tumors 24 Hours after Treatment with Saline (n = 6) or
200 mg/kg ZD6126 (n = 6).
Metabolite HRMAS Extracts
Saline ZD6126 Saline ZD6126
Choline 1.94 ± 0.3 1.11 ± 0.4 3.23 ± 0.8 2.96 ± 0.8
PC 2.34 ± 0.3 0.65 ± 0.3* 1.03 ± 0.2 0.36 ± 0.03*
GPC 1.80 ± 0.2 0.52 ± 0.1* 1.34 ± 0.2 0.74 ± 0.11y
tCho 6.08 ± 0.8 2.28 ± 0.5* 5.60 ± 0.7 4.07 ± 0.7
PC/GPC 1.32 ± 0.07 1.32 ± 0.42 0.82 ± 0.14 0.58 ± 0.15
Lactate 34.2 ± 11 14.02 ± 2.5 6.24 ± 0.92 7.70 ± 0.73
Alanine 4.34 ± 0.5 2.15 ± 0.46* 2.77 ± 0.3 2.17 ± 0.3
tCr 2.94 ± 0.3 1.55 ± 0.4* 2.94 ± 0.3 1.55 ± 0.4*
Taurine 16 ± 1.8 4.7 ± 1.4* 7.8 ± 0.3 3.07 ± 0.98*
Glycine 3.48 ± 0.31 2.53 ± 0.7 2.35 ± 0.18 1.51 ± 0.41
Acetate 0.73 ± 0.09 0.55 ± 0.15 0.94 ± 0.17 1.21 ± 0.10
Values are mean ± SEM.
*P < .02, Student’s t test.
yP < .05, Student’s t test.
564 Response of RIF-1 Fibrosarcomas to ZD6126 Madhu et al.
Neoplasia . Vol. 8, No. 7, 2006
5,6-dimethylxanthenone acetic acid (DMXAA) [13]. A sig-
nificant reduction in tCho concentration was found 24 hours
after treatment with 21 mg/kg DMXAA. Metabolite ratios,
derived from in vivo 1H MRS, showed a significant reduction
in tCho/water of C3H mammary carcinomas 24 hours after
treatment with 250 mg/kg combretastatin A4 phosphate
(CA4P), another VDA [38,39].
The difficulty of acquiring quantitative metabolite concen-
trations using volume-selective in vivo 1H MRS has resulted
in metabolite ratios being reported as surrogate markers of
tumor metabolism and response. Intriguingly, the tCho/tCr
ratio determined in vivo by HRMAS 1H MRS and high-
resolution 1H MRS of tumor extracts showed no significant
change following treatment with ZD6126. One possible ex-
planation is that ZD6126-induced necrosis and cell death
reduce cell density, resulting in the reduction of both tCho
and tCr concentrations (hence, no change in their ratio). This
highlights the need for caution when using metabolite ratios
as biomarkers of response to therapy.
We initially hypothesized that the tumor lactate/water ratio
would increase as a result of hypoxia/acidosis induced by
ZD6126-induced vascular shutdown. However, there was
no significant change in this ratio—a finding similar to that
reported for C3H mammary carcinomas 24 hours after treat-
ment with 250 mg/kg CA4P [38]. Experiments using 14C-
labeled ZD6126 have shown that the VDA itself is cleared
from tumors within 24 hours of administration (A. J. Ryan,
personal communication). Lactate is a molecule smaller than
ZD6126 and is readily extruded from tumor cells [40]; thus, it
is reasonable to assume that any lactate produced following
treatment with ZD6126 is largely cleared from the tumor
within 24 hours, hence the absence of any significant
changes in the tumor lactate/water ratio.
Both HRMAS 1H MRS and high-resolution 1H MRS of
tissue extracts showed a significant reduction in the taurine
concentration of ZD6126-treated RIF-1 tumors. Taurine is an
important organic osmolyte in mammalian cells and is abun-
dant in skeletal muscles [41]. A recent study showed that
ZD6126 treatment reduces tumor interstitial fluid pressure
[42]; thus, reduction in taurine may reflect a change in pres-
sure gradients and reduced fluid movement through the
tumor interstitium associated with the induction of cell death
and necrosis.
Tumor Biophysical Response to ZD6126
The majority of anticancer chemotherapeutic drugs kill
cells by inducing either apoptosis or necrosis. In either
process, the tissue microenvironment is altered by a reduc-
tion in intracellular space and a subsequent increase in
extracellular space. Quantitation of the spin–spin relaxation
time T2 of water, tCho, and tCr revealed no significant change
irrespective of treatment determined in vivo (Table 1) or by
HRMAS 1H MRS (data not shown). A small (ca. 20%) yet
significant increase in the T2 of water in rat GH3 prolacti-
nomas, as quantified by MRI 24 hours after treatment with
ZD6126, was recently reported and attributed to edema [43].
No significant change in T2-weighted image intensity of
C3H mammary carcinomas was reported 24 hours post-
treatment with CA4P [38]. We also hypothesized that
ZD6126-induced hemorrhagic necrosis would result in an
increase in extracellular space and, thus, in water diffusion
biomarkers. Instead, we found no significant changes in DDC
or tumor heterogeneity index (a) in vivo, suggesting no
significant changes in the biophysical characteristics of the
tumor tissue 24 hours after treatment. A similar observation
was recently reported in murine RIF-1 tumors treated with
200 mg/kg ZD6126, in which there was no significant change
in the apparent diffusion coefficient (ADC) of tumors 24 hours
posttreatment, but subsequent significant increases in ADC
at 48 and 72 hours posttreatment [44]. A significant increase
in the ADC of rat rhabdomyosarcomas 48 hours after treat-
ment with CA4P has also been reported [25]. Together, these
data suggest that any VDA-induced changes in the bio-
physical structure of the tumor tissue occur relatively slowly
and are preceded by changes in tumor metabolism.
Utility of MRS Biomarkers of Tumor Response
As a consequence of their inability to induce tumor re-
gressions, the development of VDAs has necessitated the
identification of sensitive biomarkers of tumor vascular dis-
ruption. In this regard, 1HMRImethods, with their high spatial
and temporal resolutions, are attractive, and the biomarkers
K trans (the transfer constant describing the transendothelial
transport of a low-molecular-weight contrast agent into the
extravascular extracellular space) and IAUGC (the initial
area under the gadolinium concentration–time curve), de-
rived from dynamic contrast-enhanced MRI, are particularly
suited for VDA evaluation in both preclinical and human
tumors [45]. Preclinical in vivoMRSmethods have also been
applied to assess tumor response to VDAs. Both 31P MRS
and 1H MRS have shown dramatic reductions in tumor
energetics and cell membrane proliferation in response to
VDAs, and have highlighted the potential of the bNTP/Pi
ratio and tCho as early biomarkers of tumor response to
this class of drug [13,38,39,46,47]. Similar MRS methods
have also been used for the preclinical assessment of other
novel targeted cancer therapeutics, and it is clear from these
studies that the determination of tCho by 1H MRS in vivo also
provides a robust biomarker of tumor response [14,48], in
contrast to those derived by 31P MRS where evidence of
objective tumor response is unclear [14,49]. Recently, 1H
MRS has been successfully used in the clinic to quantify
tCho concentrations of locally advanced breast cancer be-
fore and after neoadjuvant chemotherapy to predict response
[15]. Significant reductions in tCho were reported post-
treatment, further highlighting the potential utility of tCho as
a biomarker of tumor response.
In conclusion, we have shown that quantitation of tCho
by 1H MRS in vivo is a sensitive biomarker of both the pro-
gression and the response of RIF-1 tumors to the VDA
ZD6126. Tumor tCho concentration was significantly re-
duced 24 hours after treatment with 200 mg/kg ZD6126 and
appeared to precede any changes in the biophysical proper-
ties of the tissue. HRMAS 1H MRS and high-resolution 1H
MRS of tissue extracts showed significant reductions in
the concentration of PC and GPC (constituents of the tCho
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resonance detected in vivo), thereby validating tCho re-
sponse. Quantitation of tCho (mM) by in vivo 1H MRS may
provide a noninvasive biomarker of early tumor response
to VDAs.
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